<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04651569</url>
  </required_header>
  <id_info>
    <org_study_id>HD-IFOel</org_study_id>
    <nct_id>NCT04651569</nct_id>
  </id_info>
  <brief_title>An Analysis of the Efficacy of High Dose Isofosfamide Through Elastomer</brief_title>
  <official_title>A Multicentre, Retrospective, Observational Study to Analyse the Efficacy of High Dose Isofosfamide Administered Through Elastomer in Patients With Relapsed/ Refractory Osteosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicentre, observational, retrospective study to analyse the efficacy of high dose&#xD;
      isofosfamide thorugh elastomer in patients with relapsed/ refractory osteosarcoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Evaluated during the first 4 months at the end of treatment</time_frame>
    <description>Disease remission or disease progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>growth modulation index - GMI</measure>
    <time_frame>Evaluation to be recorded at each disease assessment through imaging (PET/CT/MRI)</time_frame>
    <description>ratio of time to progression (TTP) with nth line of therapy (TTPn) to the most recent prior line of therapy (TTPn-1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>toxicity according to CTCAE v.5.0</measure>
    <time_frame>Evaluation to be recorded at each disease assessment through imaging (PET/CT/MRI)</time_frame>
    <description>Disease evaluation</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Osteosarcoma Recurrent</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational study</intervention_name>
    <description>none, Observational study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with relapsed/ refractory osteosarcom&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of high risk relapsed/ refractory osteosarcoma&#xD;
&#xD;
          -  Aged &lt;= 40 years at the beginning of treatment&#xD;
&#xD;
          -  at least one completed cycle of HD IFO through elastomer (14g/mq) in 14 days&#xD;
&#xD;
          -  disease evaluation according to RECIST criteria v.1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celeste Cagnazzo, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>AOU Città della Salute e della Scienza di Torino</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Franca Fagioli, MD</last_name>
    <phone>+39 011 313 5230</phone>
    <email>franca.fagioli@unito.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Tirtei, MD</last_name>
    <phone>+39 011 693 7250</phone>
    <email>elisa.tirtei@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Longhi, MD</last_name>
      <phone>+39 051 6366411</phone>
      <email>alessandra.longhi@ior.it</email>
    </contact>
    <contact_backup>
      <last_name>Antonio Carella, PhD</last_name>
      <phone>+39 051/6366111</phone>
      <email>antonio.carella@ior.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Meyer</name>
      <address>
        <city>Florence</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale dei Tumori - S.C. Pediatria</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Meazza, MD</last_name>
      <phone>022390</phone>
      <phone_ext>2588</phone_ext>
      <email>cristina.meazza@istitutotumori.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regina Elena National Cancer Institute IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Virginia Ferraresi, MD</last_name>
      <phone>+39 06 52666919</phone>
      <email>virginia.ferraresi@ifo.gov.it</email>
    </contact>
    <contact_backup>
      <last_name>Silvia Bastucci</last_name>
      <phone>06-52666780</phone>
      <email>silvia.bastucci@ifo.gov.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>OIRM - AOU Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Tirtei, MD</last_name>
      <phone>+39 011 693 5270</phone>
      <email>elisa.tirtei@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Celeste Cagnazzo, PhD</last_name>
      <phone>+39 011 693 5270</phone>
      <email>celeste.cagnazzo@unito.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 25, 2020</study_first_submitted>
  <study_first_submitted_qc>December 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2020</study_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna</investigator_affiliation>
    <investigator_full_name>Prof. Franca Fagioli</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteosarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

